Loading clinical trials...
Loading clinical trials...
A Phase Ib/II, Open-Label, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and Subsequently in Patients With Non-Small-Cell Lung Cancer
Conditions
Interventions
AZD9150
Durvalumab
+5 more
Locations
6
United States
Research Site
Lafayette, Indiana, United States
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Nashville, Tennessee, United States
Research Site
Dallas, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Fairfax, Virginia, United States
Start Date
February 7, 2018
Primary Completion Date
January 17, 2020
Completion Date
March 28, 2024
Last Updated
August 21, 2024
NCT06815575
NCT05514132
NCT05508334
NCT04564027
NCT04907851
NCT03518606
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions